Evaluation of ribavirin in the treatment of acute hepatitis.

摘要: In this double-blind, placebo-controlled study, treatment of 60 acute hepatitis patients with ribavirin resulted in a more rapid reduction abnormal laboratory values when compared the placebo group. Moreover, improved clinical status as reflected by increased appetite resultant weight gain was noted to be significantly greater ribavirin-treated patients. Ribavirin well tolerated. With dosage regimen, there were no side effects or changes that could associated drug-related toxicity. Since A is one most common viral infections afflicting Indian population, use safe and effective therapeutic agent, such ribavirin, will necessary treat these cases.